Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B

Hye Yeon Chon, Yeon Seok Seo, Jung Il Lee, Byung Seok Kim, Byoung Kuk Jang, Sang Gyune Kim, Ki Tae Suk, In Hee Kim, Jin Woo Lee, Young Eun Chon, Moon Young Kim, Soung Won Jeong, Han Ah Lee, Sun Young Yim, Soon Ho Um, Hyun Woong Lee, Kwan Sik Lee, Jeong Eun Song, Chang Hyeong Lee, Woo Jin ChungJae Seok Hwang, Jeong Ju Yoo, Young Seok Kim, Dong Joon Kim, Chang Hun Lee, Jung Hwan Yu, Yeon Jung Ha, Mi Na Kim, Joo Ho Lee, Seong Gyu Hwang, Seong Hee Kang, Soon Koo Baik, Jae Young Jang, Sang Jun Suh, Young Kul Jung, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang Hyub Han, Hyung Joon Yim, Seung Up Kim

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Objective The liver stiffness-based risk prediction models predict hepatocellular carcinoma (HCC) development. We investigated the influence of antiviral therapy (AVT) on liver stiffness-based risk prediction model in patients with chronic hepatitis B (CHB). Methods Patients with CHB who initiated AVT were retrospectively recruited from 13 referral Korean institutes. The modified risk estimation for hepatocellular carcinoma in chronic hepatitis B (mREACH-B) model was selected for the analysis. Results Between 2007 and 2015, 1034 patients with CHB were recruited. The mean age of the study population (639 men and 395 women) was 46.8 years. During AVT, the mREACH-B score significantly decreased from the baseline to 3 years of AVT (mean 9.21 → 7.46, P < 0.05) and was maintained until 5 years of AVT (mean 7.23, P > 0.05). The proportion of high-risk patients (mREACH-B score ≥11) was significantly reduced from the baseline to 2 years of AVT (36.4% → 16.4%, P < 0.001) and was maintained until 5 years of AVT (12.2%, P > 0.05). The mREACH-B scores at baseline and 1 year of AVT independently predicted HCC development (hazard ratio = 1.209-1.224) (all P < 0.05). The cumulative incidence rate of HCC was significantly different at 5 years of AVT among risk groups (high vs. high-intermediate vs. low-intermediate vs. low) from baseline (4.5% vs. 3.2% vs. 1.5% vs. 0.8%) and 1 year (11.8% vs. 4.6% vs. 1.8% vs. 0.6%) (all P < 0.05, log-rank tests). Conclusions The mREACH-B score was dynamically changed during AVT. Thus, repeated assessment of the mREACH-B score is required to predict the changing risk of HCC development in patients with CHB undergoing AVT.

Original languageEnglish
Pages (from-to)885-893
Number of pages9
JournalEuropean Journal of Gastroenterology and Hepatology
Issue number6
Publication statusPublished - 2021 Jun 1

Bibliographical note

Funding Information:
The study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2019R1A2C4070136). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.

All Science Journal Classification (ASJC) codes

  • Medicine(all)


Dive into the research topics of 'Dynamics of liver stiffness-based risk prediction model during antiviral therapy in patients with chronic hepatitis B'. Together they form a unique fingerprint.

Cite this